Aardvark Therapeutics’ (AARD) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “outperform” rating reissued by investment analysts at Royal Bank of Canada in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $21.00 target price on the stock. Royal Bank of Canada’s target price would suggest a potential upside of 167.52% from the company’s previous close.

AARD has been the topic of several other research reports. Morgan Stanley assumed coverage on Aardvark Therapeutics in a report on Monday, March 10th. They issued an “overweight” rating and a $29.00 target price on the stock. Bank of America increased their price objective on Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price target on shares of Aardvark Therapeutics in a research note on Tuesday.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock traded up $0.34 during trading hours on Tuesday, reaching $7.85. 19,094 shares of the stock were exchanged, compared to its average volume of 139,045. Aardvark Therapeutics has a 52-week low of $6.79 and a 52-week high of $19.58.

Insider Activity

In related news, CEO Tien-Li Lee purchased 16,542 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the completion of the transaction, the chief executive officer now owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nelson Sun purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the transaction, the chief financial officer now owns 99,484 shares in the company, valued at approximately $1,591,744. This represents a 11.18 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.